Published in Circulation on January 01, 1978
Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol (2008) 1.95
Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol (2008) 1.35
Mechanisms of Post-Infarct Left Ventricular Remodeling. Drug Discov Today Dis Mech (2007) 1.16
Model-based design of mechanical therapies for myocardial infarction. J Cardiovasc Transl Res (2010) 1.11
Steroid administration after myocardial infarction promotes early infarct expansion. A study in the rat. J Clin Invest (1987) 0.92
Influence of methylprednisolone of the sequential redistribution of cathepsin D and other lysosomal enzymes during myocardial ischemia in rabbits. J Clin Invest (1978) 0.91
Influence of methylprednisolone on ultrastructural and cytochemical changes during myocardial ischemia. Selective effects on various cell inclusions and organelles including lysosomes. Am J Pathol (1978) 0.89
Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res (2015) 0.87
Structural composition of myocardial infarction scar in middle-aged male and female rats: does sex matter? J Histochem Cytochem (2013) 0.77
Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem cells other than cardiomyocyte renewal. Springerplus (2012) 0.77
Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach. Mol Cell Ther (2015) 0.76
Phagocytic activation of human neutrophils by the detergent component of fluosol. Am J Pathol (1992) 0.75
Mechanisms of cell death in acute myocardial infarction: pathophysiological implications for treatment. Neth Heart J (2001) 0.75
Ineffectiveness of methylprednisolone to reduce infarct size in experimental coronary occlusion. Basic Res Cardiol (1982) 0.75
An experimental study on use of 7T MRI for evaluation of myocardial infarction in SD rats transfected with pcDNA 3.1(+)/VEGF121 plasmid. Am J Transl Res (2016) 0.75
Nerve Growth Factor Secretion From Pulp Fibroblasts is Modulated by Complement C5a Receptor and Implied in Neurite Outgrowth. Sci Rep (2016) 0.75
Multivessel myocardial infarction: a window to future treatments of myocardial infarction. Heart Asia (2010) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest (1974) 4.42
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest (1994) 4.28
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation (1993) 3.68
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Aortic stenosis. Circulation (1968) 3.49
Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J (1981) 3.48
Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation (1993) 3.29
Sudden cardiac death triggered by an earthquake. N Engl J Med (1996) 3.27
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation (2001) 3.15
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol (1974) 3.09
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol (1995) 3.00
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
Nerve sprouting and sudden cardiac death. Circ Res (2000) 2.80
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest (1975) 2.58
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation (2000) 2.44
Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J (1981) 2.43
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Nonbacterial thrombotic endocarditis: a review. Am Heart J (1987) 2.34
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb (1994) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28
Dynamics of intramural and transmural reentry during ventricular fibrillation in isolated swine ventricles. Circ Res (2001) 2.24
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol (1990) 2.22
Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol (1978) 2.21
Coronary-artery spasm. N Engl J Med (1978) 2.20
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med (1980) 2.20
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med (1980) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation (1971) 2.15
Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol (1965) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med (1980) 2.08
Does reperfusion extend necrosis? A study in a single territory of myocardial ischemia--half reperfused and half not reperfused. Circulation (1990) 2.08
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA (2001) 2.07
Heart transplantation in patients 70 years of age and older: initial experience. Ann Thorac Surg (1996) 2.04
Unruptured sinus of Valsalva aneurysm. Am J Cardiol (1975) 2.04
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01
Discrimination of human coronary artery atherosclerotic lipid-rich lesions by time-resolved laser-induced fluorescence spectroscopy. Arterioscler Thromb Vasc Biol (2001) 1.99
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA (1996) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Modification of myocardial infarction size after coronary occlusion. Ann Intern Med (1973) 1.98
The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97